

PENDING CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-30. **(Canceled)**

31. **(Previously Presented)** A molecular conjugate comprising a human monoclonal antibody that binds to human dendritic cells, linked to an antigen, wherein the antibody comprises heavy chain and light chain variable regions which comprise the amino acid sequences shown in SEQ ID NO:2 and SEQ ID NO:4, respectively.

32-33. **(Canceled)**

34. **(Previously Presented)** A molecular conjugate comprising a monoclonal antibody that binds to the human macrophage mannose receptor, linked to Pmel-17 antigen, wherein the antibody comprises heavy chain and light chain variable regions which comprise the amino acid sequences shown in SEQ ID NO:2 and SEQ ID NO:4, respectively.

35. **(Previously Presented)** A molecular conjugate comprising a monoclonal antibody that binds to the human macrophage mannose receptor, linked to Pmel-17 antigen, wherein the molecular conjugate is encoded by the nucleotide sequence shown in SEQ ID NO:8.

36-37. **(Canceled)**

38. **(Previously Presented)** A composition comprising a molecular conjugate according to claim 31, 34, 35 or 60, and a pharmaceutically acceptable carrier.

39. **(Previously Presented)** The composition of claim 38 further comprising an adjuvant.

40-50. **(Canceled)**

51. **(Previously Presented)** The molecular conjugate of claim 31, wherein the antibody binds to the human macrophage mannose receptor.

52. **(Previously Presented)** The molecular conjugate of claim 31, produced as a recombinant fusion protein or a chemical conjugate.

53-59. **(Canceled)**

60. **(Previously Presented)** A molecular conjugate comprising a monoclonal antibody that binds to the human macrophage mannose receptor, linked to NY-ESO-1 antigen, wherein the antibody comprises heavy chain and light chain variable regions which comprise the amino acid sequences shown in SEQ ID NO:2 and SEQ ID NO:4, respectively.